Market Overview

Mylan Is 'Comfortable Moving Forward' With Acquisition Of Sweden-Based Meda


Mylan NV (NASDAQ: MYL) announced in early February it had entered into an agreement to acquire Sweden-based Meda.

Following the breakup of Pfizer Inc. (NYSE: PFE)'s proposed merger with Allergan plc Ordinary Shares (NYSE: AGN), investors are focusing in on other active M&A deals within the sector.

Bloomberg reported on Wednesday that Mylan remains "comfortable moving forward" with its proposed $7.2 billion acquisition of Meda.

Related Link: Investors Applaud Ending Of Pfizer-Allergan Deal

Mylan moved its headquarters from Pittsburgh to the Netherlands last year following its acquisition of Abbott Laboratories' generic drug business in international markets including Europe.

Shares of Mylan were trading higher by nearly 5 percent early Wednesday afternoon.


Related Articles (MYL)

View Comments and Join the Discussion!

Posted-In: abbott laboratoriesBiotech M&A News Health Care Global Trading Ideas General